CEO: Jonathan C. Javitt, M.D., M.P.H.

Visit Website

There are more than 100 suicides each day in the United States, yet, there is no approved therapeutic for the treatment of bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Many commonly used antidepressants are known to have the potential to trigger suicide in certain populations. NeuroRX is developing a sequential drug treatment regimen, NRX-100 & NRX-101, for Bipolar Depression in patients with Acute Suicidal Ideation & Behavior. NRX-101 is an oral, outpatient therapy intended to extend the rapid, antidepressant and anti-suicidal effect observed in clinical studies of NRX-100 (ketamine). Ketamine is an FDA-approved anesthetic. 

NRX-101 has been awarded Fast Track Designation and Breakthrough Therapy Designation by the FDA. NeuroRX has also started to investigate their treatments for PTSD in patients with ASIB.